Drugs / JMKX000197
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06740019 | Dec 2024 → Dec 2025 overdue | pleural disorder | Jemincare | Recruiting | No outcome recorded |
| Phase 1 | NCT05923515 | May 2023 → Apr 2025 | pleural neoplasm | Jemincare | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07649369 | Aug 2026 → Jan 2028 expected | pleural neoplasm | Shanghai Jeyou Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JMKX000197 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07649369 ↗ |
| Route | Other | “Intrapleural administration” NCT07649369 ↗ |